Literature DB >> 15955934

Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis.

L Mosconi1, W-H Tsui, S De Santi, J Li, H Rusinek, A Convit, Y Li, Madhu Boppana, M J de Leon.   

Abstract

BACKGROUND: To facilitate image analysis, most recent 2-[18F]fluoro-2-deoxy-d-glucose PET (FDG-PET) studies of glucose metabolism (MRglc) have used automated voxel-based analysis (VBA) procedures but paradoxically none reports hippocampus MRglc reductions in mild cognitive impairment (MCI) or Alzheimer disease (AD). Only a few studies, those using regions of interest (ROIs), report hippocampal reductions. The authors created an automated and anatomically valid mask technique to sample the hippocampus on PET (HipMask).
METHODS: Hippocampal ROIs drawn on the MRI of 48 subjects (20 healthy elderly [NL], 16 MCI, and 12 AD) were used to develop the HipMask. The HipMask technique was applied in an FDG-PET study of NL (n = 11), MCI (n = 13), and AD (n = 12), and compared to both MRI-guided ROIs and VBA methods.
RESULTS: HipMask and ROI hippocampal sampling produced significant and equivalent MRglc reductions for contrasts between MCI and AD relative to NL. The VBA showed typical cortical effects but failed to show hippocampal MRglc reductions in either clinical group. Hippocampal MRglc was the only discriminator of NL vs MCI (78% accuracy) and added to the cortical MRglc in classifying NL vs AD and MCI vs AD.
CONCLUSIONS: The new HipMask technique provides accurate and rapid assessment of the hippocampus on PET without the use of regions of interest. Hippocampal glucose metabolism reductions are found in both mild cognitive impairment and Alzheimer disease and contribute to their diagnostic classification. These results suggest re-examination of prior voxel-based analysis 2-[18F]fluoro-2-deoxy-d-glucose PET studies that failed to report hippocampal effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15955934     DOI: 10.1212/01.WNL.0000163856.13524.08

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  132 in total

Review 1.  The concept of FDG-PET endophenotype in Alzheimer's disease.

Authors:  Emmanuel H During; R S Osorio; F M Elahi; L Mosconi; M J de Leon
Journal:  Neurol Sci       Date:  2011-06-01       Impact factor: 3.307

2.  Increased regional cerebral glucose uptake in an APP/PS1 model of Alzheimer's disease.

Authors:  Géraldine Poisnel; Anne-Sophie Hérard; Nadine El Tannir El Tayara; Emmanuel Bourrin; Andreas Volk; Frank Kober; Benoit Delatour; Thierry Delzescaux; Thomas Debeir; Thomas Rooney; Jésus Benavides; Philippe Hantraye; Marc Dhenain
Journal:  Neurobiol Aging       Date:  2011-11-12       Impact factor: 4.673

3.  Maternal age affects brain metabolism in adult children of mothers affected by Alzheimer's disease.

Authors:  Lisa Mosconi; Wai Tsui; John Murray; Pauline McHugh; Yi Li; Schantel Williams; Elizabeth Pirraglia; Lidia Glodzik; Susan De Santi; Shankar Vallabhajosula; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2011-04-22       Impact factor: 4.673

4.  Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents.

Authors:  Lisa Mosconi; Juha O Rinne; Wai H Tsui; John Murray; Yi Li; Lidia Glodzik; Pauline McHugh; Schantel Williams; Megan Cummings; Elizabeth Pirraglia; Stanley J Goldsmith; Shankar Vallabhajosula; Noora Scheinin; Tapio Viljanen; Kjell Någren; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2012-04-11       Impact factor: 4.673

5.  Translational medicine lessons from flurizan's failure in Alzheimer's disease (AD) trial: Implication for future drug discovery and development for AD.

Authors:  Hong I Wan; J Steve Jacobsen; J Lynn Rutkowski; Giora Z Feuerstein
Journal:  Clin Transl Sci       Date:  2009-06       Impact factor: 4.689

6.  Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease.

Authors:  David S Karow; Linda K McEvoy; Christine Fennema-Notestine; Donald J Hagler; Robin G Jennings; James B Brewer; Carl K Hoh; Anders M Dale
Journal:  Radiology       Date:  2010-09       Impact factor: 11.105

Review 7.  Perturbations of neural circuitry in aging, mild cognitive impairment, and Alzheimer's disease.

Authors:  Stephanie L Leal; Michael A Yassa
Journal:  Ageing Res Rev       Date:  2013-02-04       Impact factor: 10.895

Review 8.  Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease.

Authors:  Lisa Mosconi; Alberto Pupi; Mony J De Leon
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

9.  Periodontal disease associates with higher brain amyloid load in normal elderly.

Authors:  Angela R Kamer; Elizabeth Pirraglia; Wai Tsui; Henry Rusinek; Shankar Vallabhajosula; Lisa Mosconi; Li Yi; Pauline McHugh; Ronald G Craig; Spencer Svetcov; Ross Linker; Chen Shi; Lidia Glodzik; Schantel Williams; Patricia Corby; Deepak Saxena; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2014-11-05       Impact factor: 4.673

10.  Brain SPECT in subtypes of mild cognitive impairment. Findings from the DESCRIPA multicenter study.

Authors:  Flavio Nobili; Giovanni B Frisoni; Florence Portet; Frans Verhey; Guido Rodriguez; Anna Caroli; Jacques Touchon; Piero Calvini; Silvia Morbelli; Fabrizio De Carli; Ugo P Guerra; Laura A Van de Pol; Pieter-Jelle Visser
Journal:  J Neurol       Date:  2008-08-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.